Citadel Advisors’s Impax Laboratories, Inc. IPXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-60,900
| Closed | -$1.19M | – | 9654 |
|
|
2018
Q1 | $1.19M | Sell |
60,900
-2,500
| -4% | -$49.1K | ﹤0.01% | 4542 |
|
|
2017
Q4 | $1.06M | Buy |
63,400
+34,700
| +121% | +$636K | ﹤0.01% | 4581 |
|
|
2017
Q3 | $583K | Buy |
+28,700
| New | +$549K | ﹤0.01% | 5089 |
|
|
2016
Q3 | – | Sell |
-7,300
| Closed | -$210K | – | 8111 |
|
|
2016
Q2 | $210K | Buy |
+7,300
| New | +$238K | ﹤0.01% | 5770 |
|
|
2016
Q1 | – | Sell |
-9,500
| Closed | -$406K | – | 8722 |
|
|
2015
Q4 | $406K | Sell |
9,500
-700
| -7% | -$28K | ﹤0.01% | 4763 |
|
|
2015
Q3 | $359K | Sell |
10,200
-6,500
| -39% | -$293K | ﹤0.01% | 5292 |
|
|
2015
Q2 | $767K | Buy |
16,700
+8,600
| +106% | +$408K | ﹤0.01% | 4341 |
|
|
2015
Q1 | $380K | Buy |
8,100
+2,900
| +56% | +$115K | ﹤0.01% | 5329 |
|
|
2014
Q4 | $165K | Buy |
5,200
+3,300
| +174% | +$96.6K | ﹤0.01% | 6191 |
|
|
2014
Q3 | $45K | Sell |
1,900
-3,600
| -65% | -$92.2K | ﹤0.01% | 6969 |
|
|
2014
Q2 | $165K | Buy |
5,500
+1,800
| +49% | +$48.6K | ﹤0.01% | 5773 |
|
|
2014
Q1 | $98K | Sell |
3,700
-500
| -12% | -$12.5K | ﹤0.01% | 6220 |
|
|
2013
Q4 | $106K | Sell |
4,200
-3,700
| -47% | -$82.5K | ﹤0.01% | 5559 |
|
|
2013
Q3 | $162K | Sell |
7,900
-3,600
| -31% | -$74.3K | ﹤0.01% | 4962 |
|
|
2013
Q2 | $229K | Buy |
+11,500
| New | +$204K | ﹤0.01% | 4551 |
|
Citadel Advisors's IPXL Position: Q2 2018 in Review
Citadel Advisors sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 21,316 shares — an estimated $415K sold.
Citadel Advisors first reported a position in IPXL in Q2 2013 and held it in 19 quarters. The position peaked at $35.2M in Q2 2017. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.
- Citadel Advisors reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
- Citadel Advisors sold 21,316 Impax Laboratories, Inc. shares in Q2 2018, an estimated $415K.
- Citadel Advisors first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 19 quarters.
- Citadel Advisors's Impax Laboratories, Inc. position peaked at $35.2M in Q2 2017.
- 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.
Based on Citadel Advisors's 13F filing for Q2 2018, filed 10 Aug 2018.